IDO1 and neoplasm: It was showed that combination of anti-PD-1 and YIV-906 administration significantly reduced IDO and M-MDSC of Hepa 1–6 tumor, enhanced IFNg action, polarized macrophages toward M1 type, and enhanced anti-tumor effects [133].